-5%
Fezolinetant: Postmenopausal Symptoms Management (Non-Hormonal Preparation)
Indication:
Fezolinetant is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.
Dosage & Administration:
A single 45 mg Fezolinetant tablet orally once daily with or without food.Â
While using Fezolinetant, the patient should perform follow-up hepatic laboratory tests monthly for the first 3 months, at 6 months, and 9 months after initiation of therapy or when signs or symptoms suggest liver injury.
